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Human epidermal growth factor receptor 2 (HER2) is an oncogenic driver, and a well-established therapeutic target in breast and
gastric cancers. Using functional and genomic analyses of patient-derived xenografts, we previously showed that a subset
(approximately 5%) of metastatic colorectal cancer (CRC) tumors is driven by amplification or mutation of HER2. This paper reviews
the role of HER2 amplification as an oncogenic driver, a prognostic and predictive biomarker, and a clinically actionable target in
CRC, considering the specifics of HER2 testing in this tumor type. While the role of HER2 as a biomarker for prognosis in CRC
remains uncertain, its relevance as a therapeutic target has been established. Indeed, independent studies documented substantial
clinical benefit in patients treated with biomarker-driven HER2-targeted therapies, with an impact on response rates and duration
of response that compared favorably with immunotherapy and other examples of precision oncology. HER2-targeted therapeutic
strategies have the potential to change the treatment paradigm for a clinically relevant subgroup of metastatic CRC patients.
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Introduction
Few clinically actionable genetic abnormalities have been identi-
fied in primary tumors, metastases, or blood of patients with
colorectal cancer (CRC) [1–3]. While the role of human epider-
mal growth factor receptor 2 (HER2) as a biomarker for progno-
sis in CRC remains uncertain, its role as a therapeutic target is
rising [4–8]. HER2 is also emerging as a negative predictor of re-
sponse to epidermal growth factor receptor (EGFR)-targeted
treatments [9]. Hence, patients with HER2-positive CRC might
have fewer treatment options and carry an inferior prognosis. In
this review, we consider the role of HER2 in CRC as an oncogenic
driver and prognostic and predictive biomarker, present HER2
testing methods utilized specifically in patients with CRC, and
discuss clinical diagnostic and therapeutic data supporting HER2
as a novel therapeutic target in CRC.
HER2 as an oncogenic driver in CRC
HER2 is the only member of the EGFR family that does not bind
ligands; it is activated via heterodimerization with other ligand-
bound receptors [10], with the strongest mitogenic signals cre-
ated by HER2–HER3 heterodimers. HER2 overexpression, usual-
ly caused by gene amplification, allows HER2 activation even in
the absence of ligand bound to the other partners [11].
Overexpression or amplification of HER2 has been reported in
13%–20% of breast cancers [12], 7%–34% of gastric cancers [13],
and 1.9%–14.3% of lung carcinomas [14]. Diverse rates of HER2
overexpression have been reported in CRC (Table 1 [9, 15–38]),
with rates of membranous expression ranging from 2% to 11%
[16]. A number of factors may account for these differing rates,
including small study populations, different antibodies for
immunohistochemistry (IHC), analysis of distinct subgroups of
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Table 1. Incidence of HER2 overexpression and association with prognosis in CRC
HER2 testing by IHC/ISH
References Patients, N Stage Monoclonal
antibody
HER2 31, % Location Prognostic role
Ni et al. [15] 4913 – – 1.4 Colorectal Yes
Laurent-Puig et al. [9] 1795 III 4B5 Ventana 1.4 (n¼21/1457) Colon Yes for IHC/FISH only
for RFS but not OSa
Richman et al. [16] 1914 II–III A 0485 Dako 1.3 Colorectal No
1342 IV A 0485 Dako 2.2 No
Valtorta et al. [17] 1086 – 4B5 Ventana/
Hercep-Test
4.1 Colorectal Not assessed
Ingold Heppner et al. [18] 1645 I-IV Clone SP3 0.5 (1.6 total CISHþ) Colorectal Trend toward worse survival
Song et al. [19] 106 pT1, pT2, pT3 4B5 7.5 (2/3þ) Colorectal No
SP3 3.8 (2/3þ) No
Conradi et al. [20] 264 II/III rectal PATHWAY
(Ventana)
5.9 (n¼10/169
pretreatment biopsies)
Rectal Yes
Kruwszewski et al. [21] 202 II–IV A 0485 15.3 Colorectal No
Kountourakis et al. [22] 106 – NCL-CB11 2.8 membranous Colorectal No
Schuell et al. [23] 77 I–IV Hercep-Test 3 Colorectal Trend toward worse survival
Essapen et al. [24] 170 II–III HM64.13 54.1 (2þ, cytoplasmic) Colorectal Yes (cytoplasmic, stage III)
40.0 (2þ, membranous)
McKay et al. [25] 249 I–IV NCL-CB11 3.2 Colorectal No
Rossi et al. [26] 156 I–III – 4 (2/3þ) Colorectal No
Osako et al. [27] 146 – Nichirei 4.5 (HER2 ampliﬁcation) Colorectal Yes
Kapitanovic et al. [28] 221 – Ab-3 43 (n¼67/155
adenocarcinomas)
Colorectal Yes
Molecular profiling of HER2
References Patients, N Stage Method HER2 amplification, % Location Prognostic role
Ross et al. [29] 8874 – CGS 4.9 (and/or short variant alterations) Colorectal Not assessed
Shimada et al. [30] 201 I–IV CGS 5.0 Colorectal Not assessed
Gong et al. [31] 138 – NGS 5.1 Colorectal Not assessed
Schrock et al. [32] 143 – ctDNA 4 (1 HER2 activating
mutation or ampliﬁcation)
Colorectal Not assessed
Laurent-Puig et al. [9] 1795 III NGS 2.9 (5.6 alterations KRAS wild type) Colorectal For RFS and OS on anti-EGFR-based
ﬁrst-line therapy
Takegawa et al. [33] 18 – ctDNA 22 (HER2 gene copy
number ratio 1.25)
Colorectal Not assessed
Edenﬁeld et al. [34] 4110 – NGS, IHC/ISH 1.8 Colorectal Not assessed
HER2 by primary tumor location
References Patients, N Stage Method HER2 amplification, % by location Prognostic role
Weinberg et al. [35] 1602 – CISH 5.7 left colon (patients 45 years) Not assessed
2.1 left colon (patients 65 years)
Marshall et al. [36] 496 – CISH 5.4 rectum Not assessed
3.4 descending colon
1.3 right colon
Siena et al. [37] 33 (all HER2þ) IV IHC/FISH 64 distal colon Not assessed
21 rectal
15 proximal colon
Raghav et al. [38] 97 – NGS, IHC/ISH 9.3 distal For PFS on anti-EGFR-based therapy in
2nd/3rd line; not for OS5.2 proximal
Ingold Heppner et al. [18] 1645 I–IV IHC 2.1 sigmoid colon–rectum Trend toward worse survival
0.9 cecum–descending colon
aFor FISH and NGS, RFS and OS analyses performed by pooling HER2 ampliﬁcations and mutations.
CGS, comprehensive genomic sequencing; CISH, chromogenic in situ hybridization; CRC, colorectal cancer; EGFR, epidermal growth factor receptor; FISH,
ﬂuorescence in situ hybridization; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; ISH, in situ hybridization; NGS, next-gener-
ation sequencing; OS, overall survival; PFS, progression-free survival; RFS, recurrence-free survival.
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patients with heterogeneous clinico-pathologic CRC characteris-
tics, and application of diverse scoring systems [18]. More recent
studies consistently indicate that HER2 overexpression accounts
for approximately 2% of all CRCs [9, 16, 18], increasing up to 5%
in stage III [9] or IV KRAS exon 2 wild-type tumors [6, 16, 17].
HER2 testing in CRC
Although routinely used in breast and gastric cancer, IHC and fluor-
escent in situ hybridization (ISH; FISH) or silver-enhanced ISH
(SISH) techniques have not been modified for assessment of HER2
overexpression/amplification in CRC. Table 2 [13, 17, 39, 40] and
Table 2. Guidelines for HER2 testing in breast, gastric, and CRC
Negative Equivocal Positive
Breast cancer
(Wolff et al. [39])
IHC score 0: absence of staining or
10% weak incomplete membrane
staining
IHC score 1þ: incomplete faint/bare-
ly perceptible membrane staining
>10%
ISH <4 copies or HER2: CEP17 <2 in
>10% of cells
IHC score 2þ: >10% moderate com-
plete or strong or moderate incom-
plete membrane staining, 10%
strong complete membrane
staining
ISH mandatory
ISH HER2 4–6 copies or HER2: CEP17
<2 with 4 and <6 copies in
>10% of cells
IHC score 3þ: >10% strong com-
plete membrane staining
ISH not mandatory
ISH 6 copies or HER2: CEP17 2 in
>10% of cells
Gastric cancer sur-
gical specimen
(Ru¨schoff et al.
[13])
IHC score 0: no reactivity or mem-
branous reactivity in <10% of
tumor cells
IHC score 1þ: faint/barely percep-
tible membranous reactivity in
10% of cells; cells reactive only in
part of their membrane
ISH <4 copies or HER2: CEP17 <1.8
IHC score 2þ: weak to moderate
complete, basolateral, or lateral
membranous reactivity in 10% of
tumor cells ISH mandatory
ISH HER2 4–6 copies or HER2: CEP17
1.8–2 in 10% of cells
IHC score 3þ: strong complete, baso-
lateral, or lateral membranous re-
activity in 10% of tumor cells
ISH not mandatory
ISH >6 copies or HER2: CEP17 >2 in
10% of cells
Gastric cancer bi-
opsy (Bartley
et al. [40])
IHC score 0: no reactivity or no mem-
branous reactivity in any tumor cell
IHC score 1þ: tumor cell clustera
with a faint/barely perceptible
membranous reactivity irrespective
of percentage of tumor cells
stained
ISH <4 copies or HER2: CEP17 <2
IHC score 2þ: tumor cell clustera
with a weak to moderate complete,
basolateral, or lateral membranous
reactivity irrespective of percentage
of tumor cells stained
ISH mandatory
ISH HER2 4–6 copies or HER2: CEP17
1.8–2.0 in 10% of cells indicates
another 20 cells should be scored
in a different target areab
IHC score 3þ: tumor cell clustera
with a strong complete, basolateral,
or lateral membranous reactivity ir-
respective of percentage of tumor
cells stained
ISH not mandatory
ISH HER2 >6 copies or HER2: CEP17
2 in 10% of cells
Colorectal cancer
VENTANA
(based on
Ru¨schoff et al.
[13])
IHC score 0: no staining or staining in
<10% of cells
IHC score 1þ: faint, barely percep-
tible in >10% of the cells; segmen-
tal or granular
ISH <4 copies or HER2: CEP17 <1.8
IHC score 2þ: weak to moderate
staining in >10% of cells; circumfer-
ential, basolateral, or lateral
ISH mandatory
ISH HER2 4–6 copies or HER2: CEP17
1.8–2 in 10% of cells
IHC score 3þ: intense in >10% of
cells; circumferential, basolateral, or
lateral
ISH mandatory
ISH HER2 >6 copies or HER2: CEP17
>2 in 10% of cells
Colorectal cancer
HERACLES
(Valtorta et al.
[17])
IHC score 0: no staining
IHC score 1þ: faint staining (segmen-
tal or granular); moderate staining
<50% of cells (any cellularity); in-
tense staining 10% cellsc
IHC score 2þ: moderate staining in
50% of cellsc
ISH mandatory if >50% cellularity
conﬁrmed following IHC retest
ISH HER2: CEP17 2 in 50% of cells
IHC score 3þ: intense staining in
50% of cellsc
ISH not mandatory; intense stain-
ing in >10% but <50% of cellsc
ISH mandatory if >10% cellularity
conﬁrmed following IHC retest
ISH HER2: CEP17 2 in 50% of cells
aAt least ﬁve consecutive cells.
bIf additional scoring does not allow a deﬁnitive result to be rendered, multiple options are feasible: (1) consultation between scorer and pathologist
regarding selection of malignant cells or tumor areas for scoring, (2) use of an alternative chromosome 17 probe in a retest to calculate the ratio, (3) select-
ing a different tumor block, (4) using genomics or an alternative analytic method to evaluate HER2 ampliﬁcation.
cCircumferential, basolateral, or lateral.
CEP, chromosome enumeration probe.
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supplementary Figure S1, available at Annals of Oncology online,
summarize current IHC/ISH testing guidelines in breast, gastric, and
CRC.
Valtorta and colleagues conducted a diagnostic study to define
specific IHC/ISH criteria to determine HER2 positivity in CRC,
and to accurately select patients with HER2-positive, KRAS wild-
type metastatic CRC (mCRC) for enrollment in the phase II
HERACLES (HER2 Amplification for ColorectaL Cancer
Enhanced Stratification) trial of HER2-targeted therapy [17].
HER2 protein expression was assessed manually by IHC using the
HercepTest antibody (Dako A/S Glostrup, Glostrup, Denmark), and
automatically using the VENTANA 4B5 antibody on the BenchMark
ULTRA platform (Ventana Medical Systems, Inc. Tucson, AZ, USA).
HER2 amplification was evaluated by FISH using a PathVysion
HER2 DNA Probe Kit (Abbott Laboratories, Abbott Park, IL), and
by SISH with a VENTANA 4B5 Inform HER2 dual-color assay on
the BenchMark ULTRA platform [17]. All samples were centrally
scored. HER2 positivity was defined as tumors with HER2 3þ score
in50% of cells by IHC, or HER2 2þ score and HER2: CEP17 ratio
2 in 50% of cells by FISH [17]. Referred to as the HERACLES
Diagnostic Criteria, these are more stringent than those adopted for
defining HER2 positivity in breast and gastric tumors.
In an archival cohort of 256 patients tested by an international
panel of HER2 expert pathologists, and a clinical validation co-
hort of 1277 patients, 5% of patients with KRAS wild-type mCRC
had HER2-positive tumors according to HERACLES Diagnostic
Criteria [17, 37]. In recent CRC studies, applying scoring consist-
ent with these criteria, the rate of HER2 positivity (IHC 2þ/3þ,
or HER2 ISH amplification) ranged from 1.6% to 6.3% [18, 41],
in contrast to the wide-ranging values previously reported
(Table 1 [9, 15–38]).
HER2 amplification in CRC has also been explored using mo-
lecular techniques such as next-generation sequencing (NGS)
and comprehensive genomic sequencing (CGS), with rates rang-
ing from 1.8% to 22.0% (Table 1 [9, 29–34]). Molecular profiling
using NGS, IHC, and chromogenic ISH (CISH)/FISH in a large
dataset of patients with HER2-overexpressing CRC revealed a
1.8% (81/4110 patients) incidence of HER2 overexpression, with
97% concordance between HER2 protein expression and gene
amplification [34]. Shimada and colleagues retrospectively
assessed the HER2 status of 201 patients with stages I–IV CRC
using IHC and FISH compared with using CGS [30]. Ten patients
(5%) whose tumors were diagnosed as HER2 positive by
HERACLES Diagnostic Criteria also had HER2 amplifications
according to CGS. HER2 status and HER2 amplifications at the
primary site were identical in all patients analyzed (P< 0.001),
indicating the utility of CGS for detecting HER2-positive CRC.
The use of liquid biopsies to determine HER2 status was first
explored using blood samples from patients with breast cancer
[42, 43] and was recently applied in patients with mCRC [32, 33].
Takegawa and colleagues analyzed circulating tumor DNA
(ctDNA) from 18 patients with cetuximab-resistant mCRC, of
which four (22%) were classified as HER2 positive [33].
Concordance of HER2 amplification between plasma ctDNA and
tissue samples was demonstrated by rebiopsy of the metastatic le-
sion of one of these four patients. In a separate analysis, Schrock
and coworkers isolated ctDNA from 143 patients with CRC and
identified five patients (4%) with HER2 activating mutations or
amplification [32].
IHC is readily available and successful trials of therapeutic
HER2 blockade have been based on IHC results. However, it is
likely that in the near future, molecular screening using NGS may
replace IHC. Although NGS is now more expensive, it has the ad-
vantage of capturing a wider range of genome abnormalities
including HER2-activating mutations (see section ‘Are HER2
mutations actionable therapeutic targets in mCRC?’) and allow-
ing quantitation of gene copy number.
Distribution and prognostic effect of HER2
in CRC
Clinical and pathologic features of HER2-positive
CRC
Tumors originating in the right or left side of the colon and rec-
tum differ in their epidemiology, pathology, mutation profile,
and presentation, likely due to distinct embryologic origins of the
proximal and distal colon [44]. Proximal, or right-sided, tumors
are more likely to be hypermethylated or to have microsatellite
instability (MSI) than distal tumors [5]. Right-sided tumors are
also more common in women and the elderly [45]. Recent meta-
analyses showed a consistent and significant worsening in overall
survival (OS) in mCRC tumors originating in the right versus the
left side of the colon [46–48].
A number of CRC studies have reported differential expression
related to the occurrence ofHER2 amplification based on clinical and
pathologic features of the tumor, including primary location (Table
1). Analysis of gene expression and DNA copy number data for
patients with CRC in the PETACC-3 adjuvant chemotherapy trial
revealed that distal carcinomas (splenic flexure, descending colon,
rectum) were more likely to be HER2 or EGFR amplified than prox-
imal carcinomas (cecum, ascending, hepatic flexure, transverse
colon) [49]. Similar results were reported in advanced CRC, with
HER2 amplifications identified using SISH correlating with a distal
location [50]. A retrospective analysis identified higher frequencies of
HER2 overexpression/amplification in rectal cancers compared with
descending colon or right colon cancers [36]. A similar trend for
more frequent HER2 overexpression in tumors of the sigmoid colon-
rectum than the cecum-descending colon was reported in a large ser-
ies of primary CRC cases [18]. In the HERACLES-A trial, among 33
patients with HER2-positive mCRC, 64% had distal tumors and 21%
had rectal tumors [37]. Retrospective data from the phase II
EXPERT-C trial, in patients with high-risk, locally advanced rectal
cancer receiving neoadjuvant capecitabine and oxaliplatin plus che-
moradiotherapy with or without cetuximab, showed a 4.3% preva-
lence of HER2 overexpression/amplification using IHC/ISH [51].
These findings are in line with the 5.4% HER2-positivity rate for rec-
tal cancers described by Marshall and colleagues [36].
In contrast to studies reporting a correlation between HER2
amplification and tumor location, other researchers have found no
such association. In the PETACC-8 FOLFOX-based adjuvant stage
III colon cancer study, no significant differences were seen between
patient groups on the basis of tumor location [9]. A retrospective
analysis of two independent cohorts of patients with mCRC
observed no significant difference in HER2 expression between
right- and left-sided primary tumors [38]. A trend toward a
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decreasing frequency of HER2-positive tumors by IHC was noted
from colon to rectum in 3/77 (4%) HER2-positive specimens, but
this was not statistically significant (P¼ 0.251) [23]. Several studies
have considered the relationship between KRAS status and HER2
amplification in CRC. In a meta-analysis of 3256 patients with
mCRC, HER2 amplification using FISH and gene copy number
variation was associated with KRAS/BRAF wild-type status at all
disease stages: 5.2% wild type versus 1.0% mutated tumors
(P< 0.0001) in stage IV, and 2.1% versus 0.2%, respectively, in
stages II–III (P¼ 0.01) [16]. Similarly, in the PETACC-8 study,
HER2 alterations determined using NGS, IHC, and FISH were
detected in 42 (5.6%) patients with KRAS wild-type tumors com-
pared with 22 (2.4%) patients with RAS mutation (P< 0.001) [9].
HER2 amplifications according to SISH were also correlated with
KRAS wild-type status in 191 patients with mCRC and distant
metastases, but only with borderline significance (P¼ 0.052) [50].
In a meta-analysis of 30 studies enrolling 4942 patients with
CRC, HER2 expression assessed by IHC was significantly higher
in patients with Duke’s stage C/D tumors compared with Duke’s
stage A/B tumors [odds ratio (OR) 0.335, 95% confidence inter-
val (CI) 0.198–0.568; P< 0.001], and in patients with versus
without lymph node metastasis (OR 1.987, 95% CI 1.209–3.265;
P¼ 0.007) [52]. However, no significant association was found
between HER2 expression and CRC location (rectal versus colon;
OR 1.123, 95% CI 0.858–1.468; P¼ 0.399).
Prognostic role of HER2 in CRC
The prognostic role of HER2 in CRC remains uncertain. A negative
prognostic impact of HER2 overexpression was proposed in earlier
studies [27, 28], but more recent trials have found no association
between HER2 amplification and outcome (Table 1 [16, 19, 21, 22,
25]). However, in one of the largest study cohorts examined (1645
patients with stages I–IV CRC), a trend toward worse OS was
reported for the 26 (1.6%) patients with HER2-positive disease
compared with those with HER2-negative disease [18]. HER2 was
also identified as a poor prognostic indicator in the PETACC-8
study in patients with stage III colon cancer [9]. HER2 alterations
were present in 66/1689 evaluated patients (3.9%). HER2 concord-
ant amplification-positive status by both NGS and FISH, and HER2
mutation status determined by NGS, were associated with shorter
time to recurrence [hazard ratio (HR) 1.9, 95% CI 1.1–3.2;
P¼ 0.03] and shorter OS (HR 1.7, 95% CI 0.9–3.2; P¼ 0.045). This
prognostic value was maintained after adjustment for age, treat-
ment, RAS mutation, histologic grade, tumor location, pT and pN
status, bowel obstruction or perforation, and vascular or lymphatic
invasion. Assessment of the potential prognostic effect of HER2
amplifications in CRC is hindered by the low incidence of these
alterations, potentially explaining the inconsistent results of studies
addressing this question. Nevertheless, based on available data, it
appears that the negative prognostic effect of HER2 is not as marked
as that of other alterations such as BRAFmutation.
HER2 as a negative biomarker for EGFR-
targeted treatments in CRC
CRCs are a molecularly heterogeneous group of tumors that often
harbor mutations in KRAS, BRAF, or PIK3CA, as well as HER2
amplifications. These genetic alterations confer resistance to
EGFR-targeted therapies in patients with CRC [1, 53, 54], although
currently only selection based on RAS status is recommended for
excluding patients from anti-EGFR treatment [55–57]. Using data
generated from patient-derived mCRC xenografts, Bertotti and
coworkers identified HER2 amplification as a negative predictor of
response to cetuximab [1, 4]. Two retrospective clinical series sup-
ported that activation of HER2 signaling causes resistance to
cetuximab [58, 59]. Yonesaka and colleagues evaluated the clinical
impact of de novo HER2 amplification in 233 cetuximab-treated
patients [58]. Median progression-free survival (PFS) and OS were
almost halved in patients with HER2-amplified (n¼ 13) versus
nonamplified tumors (n¼ 220): PFS 89 versus 149 days, respect-
ively; OS 307 versus 515 days, respectively; P¼ 0.0013, log-rank
test [58]. Survival outcomes were negatively influenced by HER2
gene copy number in a second series of 170 patients with KRAS
wild-type mCRC treated with cetuximab or panitumumab alone
or in combination with chemotherapy [59]. Raghav and coworkers
analyzed the impact of HER2 amplification on the efficacy of anti-
EGFR monoclonal antibody therapy in RAS and BRAF wild-type
mCRC [38]. They tested HER2 amplification in a first cohort of 97
patients using IHC and dual ISH (HER2: CEP17 2.2), and vali-
dated their findings in a second cohort of 99 patients, which com-
prised 37 cases of HER2 amplification identified by NGS (HER2
gene copy number 4) and 62 HER2 nonamplified control
patients pretreated with anti-EGFR antibodies. Median PFS on
anti-EGFR therapy was significantly shorter in patients with HER2
amplification versus non-HER2-amplification (2.9 months versus
8.1 months, HR 5.0, P< 0.0001). These findings were confirmed
in the validation cohort, in which 69 patients received anti-EGFR
treatment after first-line therapy; median PFS was significantly
shorter for patients harboring HER2-amplified versus nonampli-
fied tumors (2.8 months versus 9.3 months, HR 6.6, P< 0.0001).
Notably, these subgroups had a similar OS (P¼ 0.86) and PFS
while on first-line therapy (P¼ 0.62) [38]. Finally, in the
HERACLES-A study, conducted exclusively in HER2-positive
mCRC, Sartore-Bianchi and colleagues reported that patients
who had previously received panitumumab or cetuximab, evalu-
able according to rigorous clinical criteria, were resistant to such
therapy [6].
As summarized in Table 3 [4, 6, 37, 38, 58, 59], the results from
these experimental and clinical studies concur that HER2 activa-
tion substitutes for EGFR dependence in a fraction of patients
with CRC. From a clinical perspective, this notion could poten-
tially impact on optimal therapeutic sequence; however, it should
be interpreted with caution since the data are retrospective and
need to be validated in prospective clinical studies of patients
treated with cetuximab or panitumumab.
HER2 as a novel therapeutic target in CRC
HER2 has been investigated as a therapeutic target in mCRC in
several small studies during the last decade, but with differing
outcomes (Table 4 [7, 37, 60, 61]). A phase II study assessed the
combination of trastuzumab and FOLFOX therapy as second- or
third-line treatment of patients with mCRC [61]. Notably,
patients with IHC HER2 2þ tumors were eligible for enrollment
and no ISH testing was planned. Overall, 26 of 653 (4%) of
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screened tumor blocks scored HER2 2þ. Among 21 evaluable
patients, 5 (24%) achieved a partial response. However, the low
rate of HER2 positivity precluded completion of the trial. Results
of a subsequent phase II study of first- or second-line trastuzu-
mab plus irinotecan in nine patients with HER2-overexpressing
advanced CRC were also reported [60]. HER2 overexpression by
IHC was evident in 11 of 138 (8.0%) screened tumors (HER2 2þ
in 5 patients and HER2 3þ in 6 patients). Partial responses were
observed in five of seven evaluable patients (71%), with responses
maintained for 6 weeks in four patients. The median survival
time was 14 months. The study was closed prematurely due to
lack of accrual.
A case report was also published of two patients with mCRC
and liver metastases who responded to capecitabine, oxaliplatin,
and lapatinib while on a clinical trial, but HER2 status was not
determined in these patients [62].
The inconclusive efficacy findings and poor accruals observed
in these studies most likely relate to the absence of a number of
important prerequisites in study design, including a mechanistic-
ally based HER2-targeted preclinical strategy, patient selection
using a validated HER2 scoring system, and a preplanned sample
size based on the actual estimated incidence of HER2 amplifica-
tion. Moreover, due to concomitant chemotherapy in some stud-
ies, it is difficult to establish the specific contribution of HER2
blockade on therapeutic outcome.
Using xenografts derived from patients with mCRC in pre-
clinical therapeutic trials, Bertotti and colleagues identified
amplified HER2 as an effective therapeutic target in cetuximab-
resistant CRC [1, 4]. Patient-derived mCRC xenografts with
HER2 amplification were sensitive to HER2-blockade with tras-
tuzumab in combination with lapatinib, but not to either agent
alone. These preclinical data formed a strong rationale for
Table 3. Studies addressing the predictive role of HER2 to EGFR-targeted therapies in mCRC
Reference Patients, N HER2 amplification, %
of patients
Method Prediction of resistance to
cetuximab or panitumumab
Bertotti et al. [4] 85 13.6
(KRAS WT, cetuximab- or
panitumumab-resistant)
IHC/FISH (LSI HER2/CEP17
PathVysion probe)
HER2 ampliﬁcation or overexpres-
sion in 6/44 (13.6%) patients
with KRAS WT tumors without
objective response to cetuximab
or panitumumab versus 0/45
(0%) patients with objective re-
sponse (P<0.05)a
Yonesaka et al. [58] 233 (182 KRAS WT) 5.6
(6.0 KRAS WT)
FISH (LSI HER2 SO/CEP17
PathVysion probe)
Median OS longer in HER2 nonam-
pliﬁed versus HER2-ampliﬁed
(515 versus 307 days, P¼0.0013)b
Martin et al. [59] 162 (KRAS WT) 20 (HER2: CEP17 2 in
10% of tumor cells)
6 [HER2: CEP17 2 in
90% of tumor cells
(HER2-all-A proﬁle)]
FISH (LSI HER2-neu/CEP17
probe)
Median PFS longer in HER2 FISHþ
versus HER2 FISH– (7.4 versus 3.9
months, HR 2.00, 95% CI 1.42–
2.83, P<0.0001)c
Sartore-Bianchi et al. [6]
and Siena et al. [37]
33 [36] 100 IHC/FISH No objective response to cetuxi-
mab or panitumumab in 15/27
patients [6] with HER2-positive
tumors assessed for sensitivity to
cetuximab or panitumumab
according to rigorous criteria
Raghav et al. [38] 97 (cohort 1);
99 (cohort 2)
14% cohort 1; RAS/BRAF-
WT cohort 2; not
reported
IHC/ISH cohort 1d;
NGS cohort 2e
Median PFS on anti-EGFR therapy
shorter in patients with HER2-
ampliﬁed versus HER2 nonampliﬁed
tumors (2.9 versus 8.1 months, HR
5.0, P<0.0001) [cohort 1];
(2.8 versus 9.3 months, HR 6.6,
P<0.0001) [cohort 2]
aData supported by a molecularly annotated platform of patient-derived xenografts.
bAcquired HER2 ampliﬁcation in two cases of secondary resistance to cetuximab.
cHER2 FISHþ: HER2 gene copy number gain (presence of 4 copies of the HER2 gene in 40% of cells) and HER2-ampliﬁed (HER2 gene ampliﬁcation
deﬁned as HER2: CEP17 2 in 10% of cells).
dHER2 ampliﬁcation deﬁned as HER2: CEP17 2.2.
eHER2 ampliﬁcation deﬁned as HER2 4 copies.
HR, hazard ratio; mCRC, metastatic colorectal cancer; WT, wild type.
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clinical trials targeting HER2 genetic alterations in patients with
mCRC [1, 4, 63], paving the way for the HERACLES studies.
Recently, results of the HERACLES-A phase II trial of
dual HER2-targeted therapy (trastuzumab plus lapatinib) in
CRC were presented [6, 37]. This proof-of-concept trial was
conducted in patients with KRAS wild-type, HER2-positive
mCRC who were refractory to standard-of-care treatments,
including cetuximab or panitumumab. The HER2 status of the
patients was determined using the CRC-specific HERACLES
Diagnostic Criteria [17]. At the data cutoff of 28 February 2017,
33 patients had been enrolled and were evaluable for response.
Complete responses were observed in two patients (6.1%)
and partial responses in eight patients (24.2%), giving an overall
response rate (ORR) of 30.3% (Table 4) [37]. Patients with
HER2 gene copy number 9.6 had significantly longer time to
progression (median 26.6 weeks versus 13.4 weeks; P¼ 0.0001)
and longer OS (median 53.1 weeks versus 34.0 weeks;
P¼ 0.0058) than those with HER2 gene copy number<9.6 [37].
The combination regimen was well tolerated in this heavily
pretreated population (median of five prior regimens), with
no grade 4/5 adverse events and no withdrawals due to patient
request [37]. Novel methods of generating additional evidence
to make this regimen widely available in clinical practice are
needed.
Based on preliminary data from the phase II MyPathway trial,
investigating agents targeting the HER2, EGFR, BRAF, or
Hedgehog pathways in tumors for which these therapies are not
currently indicated, the CRC cohort was expanded to enroll 37
patients with HER2-amplified/overexpressed mCRC who had
exhausted standard treatments [8]. Patients received a combin-
ation of trastuzumab and pertuzumab. The ORR was 38% (95%
CI 22.2–56.4) (Table 4). Four (11%) patients had stable disease
for>4 months [8]. Median PFS was 4.6 months (95% CI 1.6–9.8)
and median OS was 10.3 months (95% CI 7.2–22.1) [7]. ORR
was higher in patients with wild-type versus mutated KRAS
(52.0% versus 0%, respectively), and in patients with left-sided
colon cancer (42.9%) or rectal cancer (45.5%) versus right-sided
colon cancer (12.5%) [7].
In support of the available preclinical and clinical data, anec-
dotal case reports of patients with HER2-positive mCRC who
have achieved substantial clinical benefit with targeted anti-
HER2 therapy have recently been published [64–66].
Table 4. Clinical studies exploiting HER2 as a target for mCRC
Reference Phase Patients, N HER2
overexpression, %
Treatment Line of treatment Objective
response rate, %
Published studies
Ramanathan et al.
[60]
II 9a 3.6 (2þ) Trastuzumab and
irinotecan
1st/2nd 71
4.3 (3þ)
Clark et al. [61] II 21b 4.0 (2þ/3þ) 5-FU, leucovorin, oxali-
platin and
trastuzumab
2nd/3rd 24
HERACLES-A; Siena
et al. [37]
II 33 21 (2þ) Trastuzumab and
lapatinib
Salvage 30.3
79 (3þ)
MyPathway;
Hainsworth et al.
[8]
II 37 100c Trastuzumab and
pertuzumab
Salvage 38
Ongoing studies
HERACLES-B; Siena
et al. [37]
II 30 100 (17, 2þ; 83, 3þ) Pertuzumab and T-
DM1
2nd/3rd Not reported
HERACLES-RESCUE;
Siena et al. [37]
II 9 100 T-DM1 Salvage Not reported
S1613
(NCT03365882)
II Not available Not reported Trastuzumab and per-
tuzumab or cetuxi-
mab and irinotecan
2nd or later Not reported
MODUL
(NCT02291289)
II Not available Not reported Capecitabine, trastuzu-
mab, and
pertuzumab
Biomarker-driven mainten-
ance therapy after ﬁrst-line
FOLFOX þ bevacizumab
induction
Not reported
NCT03384940 II Not available Not reported DS-8201 (investiga-
tional trastuzumab
conjugated with
deruxtecan)
3rd Not reported
aThe study was prematurely closed due to low accrual.
bThe low rate of HER2 positivity precluded completion of the trial.
cPatients with HER2 mutations were also eligible; see text for details.
DS-8201, trastuzumab deruxtecan; 5-FU, 5-ﬂuorouracil; T-DM1, trastuzumab emtansine.
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Challenges and open issues toward clinical
application
Are HER2 mutations actionable therapeutic targets
in mCRC?
A number of HER2 activating mutations, sometimes in concomi-
tance with HER2 amplification, have been identified in CRC.
These mutations are present in approximately 7% of CRCs, based
on TCGA data, and may co-exist with HER2 gene amplification in
around 20% of cases [63]. They are similar to those seen in breast
cancer and include kinase domain single nucleotide variations
such as V842I, V777L, and L755S, and extracellular domain muta-
tions such as S310F [1, 5, 63]. Introduction of these four mutations
into immortalized mouse colon epithelial cells triggered HER2 sig-
naling pathways, with increases in HER2, MAPK, and AKT phos-
phorylation noted relative to HER2 wild-type transduced cells
[63]. These HER2 mutations also dramatically increased the num-
ber of colonies formed in soft agar, demonstrating enhanced
anchorage-independent growth. Furthermore, these HER2-acti-
vating mutations produced resistance to the EGFR monoclonal
antibodies, cetuximab or panitumumab, when transfected into
two cetuximab-sensitive CRC cell lines [63]. In patient-derived
CRC xenografts containing the HER2-activating mutations S310Y
or L866M, treatment with trastuzumab, neratinib, or lapatinib
alone delayed tumor growth, but after 30 days, the mice developed
large tumors. However, dual HER2-targeted therapy with trastu-
zumab plus either neratinib or lapatinib produced durable tumor
regression, similar to that observed in HER2-amplified mCRC
[63]. Lack of effect of neratinib monotherapy in HER2-mutant
CRC was recently confirmed in a basket trial of 125 patients with
different tumors harboring HER2 mutations, including 12 patients
with CRC [67]. In the latter cohort, there were no objective
responses and median PFS was just 1.8 months. In the MyPathway
trial, eight patients with mCRC had tumors that harbored HER2
mutations and one of these (12.5%) achieved an investigator-
assessed objective response with the combination of pertuzumab
and trastuzumab (H. Hurwitz, personal communication). Overall,
these data indicate that monotherapy with HER2 small molecule
inhibitors is ineffective. It remains to be determined whether
HER2-directed combination therapy with monoclonal antibodies
or monoclonal antibodies plus small molecule inhibitors can be ef-
fective inHER2-mutated tumors.
What are the determinants of resistance to HER2-
directed therapies?
Understanding the mechanisms of primary and secondary resist-
ance to HER2 blockade is a priority to develop more effective and
additional lines of therapy, because 40%–50% of patients treated
within the HERACLES-A and MyPathway trials did not achieve
partial response or prolonged stable disease despite HER2 ampli-
fication [6, 8]. Moreover, even in patients displaying disease con-
trol, secondary resistance occurs in almost all cases. Preclinical
models of HER2 therapeutic blockade were carried out in quad-
ruple negative mCRC (i.e. KRAS, NRAS, PIK3CA, and BRAF
wild-type) since aberrations in one or more of these effectors
could impact on and compensate for the inhibition exerted by
HER2-directed therapy [4, 6, 7]. Based on these findings, the
HERACLES-A trial was performed in KRAS exon 2 wild-type
patients, thus positive clinical results can be applied to this subset
of patients only. Anecdotally, we treated two patients harboring
KRAS exon 2 mutations off-study, and neither obtained a
partial response (S. Siena and A. Sartore-Bianchi, personal com-
munication). The MyPathway study included patients with
KRAS-mutated CRC, but none of these patients responded to
HER2-directed therapy [7], confirming the biologic rationale
underlying resistance.
Extensive studies utilizing pre- and post-treatment tissue sam-
ples are ongoing to define the molecular basis of primary and sec-
ondary resistance to trastuzumab and lapatinib in HER2-positive
mCRC. Preliminary data obtained by molecular profiling of
plasma samples collected during the HERACLES-A trial suggest
that alterations affecting HER2 parallel pathways controlled by
receptor tyrosine kinases, and/or downstream effectors such as
RAS and PI3KA, are implicated in primary and secondary resist-
ance to HER2 blockade (G. Siravegna, unpublished data). Once
completed, these analyses may have important implications for
the selection of patients with mCRC most likely to benefit from
anti-HER2 therapies, as well as providing the basis for designing
new treatments in patients who experience disease progression.
When to test for HER2 and how an HER2-directed
therapy may integrate in the treatment algorithm
of mCRC
Based on the consistent therapeutic actionability of dual HER2
inhibition in refractory mCRC [6, 8], it is feasible that a similar
effect may be obtained by targeting HER2 in earlier lines of treat-
ment and testing for HER2 alongside other biomarkers being
assessed at the time of diagnosis of metastatic disease [68]. HER2
amplification in mCRC can be considered an orphan molecular
entity. Difficulties in developing a targeted treatment of this can-
cer, up to the level of regulatory approval, are being addressed
with tools developed in the context of international initiatives
[69]. While speculative in the absence of randomized data,
hypotheses can be made regarding clinical trials with HER2-
directed therapies aimed at defining optimal positioning and
combination partners in the treatment algorithm of mCRC
(Figure 1). National and international collaborations and transla-
tional studies designed to understand mechanisms of resistance
to HER2 inhibition will be of paramount importance to the suc-
cessful development of these trials. Based on available results
[6, 8], these studies should be restricted to KRAS exon 2 wild-
type tumors. Although data regarding the potential impact on
sensitivity exerted by other RAS mutations outside KRAS exon 2
are lacking, application of expanded RAS wild-type criteria might
be more realistic. Finally, since HER2 amplification might act as a
negative predictor of response to EGFR-targeted treatments,
HER2-directed therapy before cetuximab or panitumumab in the
continuum of care of these patients should be considered a rea-
sonable option.
Available data suggest a 30% ORR with dual HER2 inhib-
ition, which compares favorably with results of second-line
standard treatment options in patients with RAS wild-type CRC
previously treated with a first-line regimen including an anti-
EGFR component. In patients who do not receive an anti-EGFR
in first-line, second-line chemotherapy plus anti-EGFR
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(especially in RAS and BRAF selected cases [70]) might produce
good responses, but given the potential negative predictive role of
HER2 amplification, this is unlikely to be the case in this patient
population. In light of these considerations, and of the expected
lower toxicity of a chemotherapy-free regimen, a dual HER2-
targeted combination might be an optimal choice for a trial in
this setting, either after FOLFOX/FOLFIRI with an anti-EGFR or
a vascular endothelial growth factor (VEGF)-targeted compo-
nent, and compared with standard second-line options.
A hypothetical alternative might be starting with an HER2-
targeted component during first-line treatment. However, it is
uncertain whether a chemotherapy-free HER2-targeted regimen
would perform better than standard FOLFOX/FOLFIRI or
FOLFOXIRIþ/– EGFR- or VEGF-targeted options, which pro-
duce ORRs of 59%–65% in this setting [71, 72]. Therefore, a
combination of HER2-directed treatment with chemotherapy
should be considered, taking into account safety issues for the
combination and the fact that HER2 might act as a negative pre-
dictive biomarker of response to EGFR-targeted treatment. For
the latter reason, comparison between a FOLFOX/FOLFIRI back-
bone with an HER2-directed agent versus the same chemother-
apy with an anti-EGFR agent might offer a straight-forward
answer on the optimal sequencing in RAS wild-type tumors, and
whether or not to offer an anti-EGFR drug upfront to these
patients.
Conclusion
HER2 amplification is a clinically relevant genetic alteration in
mCRC as documented by the HERACLES [6, 37] and
MyPathway [7, 8] studies. This biomarker can be screened for
with established diagnostic tools [16, 17], occurs in a sizable 5%
of patients with KRAS wild-type mCRC, and can potentially act
as a predictor of lack of benefit to anti-EGFR monoclonal anti-
bodies [4].
HER2-targeted therapy compares favorably with emerging
therapeutic strategies for mCRC such as BRAF-directed therapy
and immunotherapy with checkpoint inhibitors. HER2 amplifi-
cation displays an incidence similar to that of MSI-high (MSI-H)
tumors (5%) [73] and lower than that of BRAF mutations (10%);
however, compared with BRAF-directed combinations (ORR
16%–21%; median PFS 4.2 months [74]), responses achieved so
far in clinical studies with HER2-directed therapies are higher
(ORR 30%–38% [6, 8]) and more durable (median PFS
5.2 months [6]), resembling results obtained with checkpoint
inhibitors in MSI-H tumors [75]. The toxicity of HER2-targeted
combinations is also less than BRAF- or MSI-H-directed thera-
peutics [74, 75]. Thus, HER2-directed therapies appear to recon-
cile the merits of precision medicine (rapid and deep induction
of tumor shrinkage) with those of immunotherapy (durable
responses and better tolerability).
Although evidence from phase III trials with HER2-targeted
agents is lacking, randomized studies will take a long time to
achieve results in such a selected population [69]. The strong
underlying biologic rationale [4], consistent actionability at the
therapeutic level [6, 8], and favorable comparison with other pre-
cision medicine approaches support consideration for condition-
al approval of HER2-targeted agents for clinical use by regulatory
agencies.
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